BRAF and neoplasm: This approach led to the emergence of multiple compounds targeting the tumor’s molecular alterations (e.g., Philadelphia translocation, HER2, BRAF) that are currently used to treat numerous malignancies such as leukemia (e.g., Imatinib), breast cancer (e.g., Trastuzumab), and melanoma (e.g., Vemurafenib)1–3.